2-(tetrahydro-2H-pyran-2-yl)-6-[3-(tetrahydro-2H-pyran-2-yloxy)phenyl]-2H-indazol-4-amine | 1198802-80-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 2-(tetrahydro-2H-pyran-2-yl)-6-[3-(tetrahydro-2H-pyran-2-yloxy)phenyl]-2H-indazol-4-amine
• 英文别名: 2-(oxan-2-yl)-6-[3-(oxan-2-yloxy)phenyl]indazol-4-amine
• CAS: 1198802-80-0
• 化学式: C₂₃H₂₇N₃O₃
• 分子量: 393.486
• InChiKey: OLTVYZAXVWSLLN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  71.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(tetrahydro-2H-pyran-2-yl)-6-[3-(tetrahydro-2H-pyran-2-yloxy)phenyl]-2H-indazol-4-amine 在 盐酸 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 为溶剂， 反应 2.0h， 生成 N-(6-(3-hydroxyphenyl)-1H-indazol-4-yl)cyclopropanecarboxamide
  参考文献：
  名称：

  From PIM1 to PI3Kδ via GSK3β: Target Hopping through the Kinome

  摘要：

  Selective inhibitors of phosphoinositide 3-kinase delta are of interest for the treatment of inflammatory diseases. Initial optimization of a 3-substituted indazole hit compound targeting the kinase PIM1 focused on improving selectivity over GSK3 beta through consideration of differences in the ATP binding pockets. Continued kinase cross-screening showed PI3K delta activity in a series of 4,6-disubstituted indazole compounds, and subsequent structure activity relationship exploration led to the discovery of an indole-containing lead compound as a potent PI3K delta inhibitor with selectivity over the other PI3K isoforms.

  DOI：

  10.1021/acsmedchemlett.7b00296
• 作为产物：
  描述：

  4-硝基-6-溴-1H-吲唑 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 palladium 10% on activated carbon 、 4-甲基苯磺酸吡啶 氢气 、 碳酸氢钠 作用下， 以 二氯甲烷 、 水 、 乙酸乙酯 、 异丙醇 为溶剂， 20.0~150.0 ℃ 、101.33 kPa 条件下， 反应 20.67h， 生成 2-(tetrahydro-2H-pyran-2-yl)-6-[3-(tetrahydro-2H-pyran-2-yloxy)phenyl]-2H-indazol-4-amine
  参考文献：
  名称：

  [EN] 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES
  [FR] DÉRIVÉS DE 4-CARBOXAMIDE INDAZOLE UTILES EN TANT QU'INHIBITEURS DE P13 KINASES

  摘要：

  这项发明涉及某些新颖的化合物。具体来说，该发明涉及具有式(I)的化合物及其盐。该发明的化合物是P13-激酶活性的抑制剂。

  公开号：

  WO2009147187A1

文献信息

• [EN] 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES<br/>[FR] DÉRIVÉS DE 4-CARBOXAMIDE INDAZOLE UTILES EN TANT QU'INHIBITEURS DE P13 KINASES
  申请人：GLAXO GROUP LTD

  公开号：WO2009147187A1

  公开（公告）日：2009-12-10

  The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of P13-kinase activity.

  这项发明涉及某些新颖的化合物。具体来说，该发明涉及具有式(I)的化合物及其盐。该发明的化合物是P13-激酶活性的抑制剂。
• 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases
  申请人：GlaxoGroupLimited

  公开号：US08163743B2

  公开（公告）日：2012-04-24

  The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of P13-kinase activity.

  本发明涉及某些新型化合物。具体来说，本发明涉及公式（I）的化合物及其盐。本发明的化合物是P13-激酶活性的抑制剂。
• 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES
  申请人：Baldwin Ian Robert

  公开号：US20110112070A1

  公开（公告）日：2011-05-12

  The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of P13-kinase activity.

  本发明涉及某些新颖化合物。具体而言，本发明涉及式(I)化合物及其盐。本发明的化合物是P13-激酶活性抑制剂。
• US8163743B2
  申请人：——

  公开号：US8163743B2

  公开（公告）日：2012-04-24
• From PIM1 to PI3Kδ via GSK3β: Target Hopping through the Kinome
  作者：Zoë A. Henley、Benjamin D. Bax、Laura M. Inglesby、Aurélie Champigny、Simon Gaines、Paul Faulder、Joelle Le、Daniel A. Thomas、Yoshiaki Washio、Ian R. Baldwin

  DOI：10.1021/acsmedchemlett.7b00296

  日期：2017.10.12

  Selective inhibitors of phosphoinositide 3-kinase delta are of interest for the treatment of inflammatory diseases. Initial optimization of a 3-substituted indazole hit compound targeting the kinase PIM1 focused on improving selectivity over GSK3 beta through consideration of differences in the ATP binding pockets. Continued kinase cross-screening showed PI3K delta activity in a series of 4,6-disubstituted indazole compounds, and subsequent structure activity relationship exploration led to the discovery of an indole-containing lead compound as a potent PI3K delta inhibitor with selectivity over the other PI3K isoforms.